THE WHAT? Waldencast reported its This autumn 2025 and full-year 2025 monetary outcomes, with income broadly flat year-on-year as the corporate continued investing in model development and medical aesthetics growth.
THE DETAILS The sweetness and wellness platform reported FY 2025 web income of US$272.1 million, broadly unchanged from 2024, with adjusted EBITDA of US$16.1 million. Fourth-quarter income totaled US$72.0 million, additionally flat year-on-year, with adjusted EBITDA of US$6.6 million.
Inside the portfolio, Obagi Medical delivered sturdy momentum, benefiting from worldwide demand and U.S. direct-to-consumer development, supported by investments tied to the launch of its injectable aesthetics platform. In the meantime, Milk Make-up expanded U.S. distribution, together with launches at Ulta Magnificence and Amazon Premium Magnificence, though softer worldwide demand weighed on general income.
Throughout the 12 months, Waldencast additionally strengthened its monetary place by means of the sale of the Obagi Japan trademark to Rohto Pharmaceutical for US$82.5 million and refinancing its credit score facility. The corporate stated it’s conducting a strategic assessment to discover choices to maximise shareholder worth.
THE WHY? The outcomes replicate Waldencast’s technique to rework its portfolio, increase into medical aesthetics, strengthen its monetary construction and place its manufacturers for long-term development.
Supply: Globnewswire
